Loading
Life sciences · Journal article
Advanced Science · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study reporting that selenium nanoparticles (SeNPs) inhibit KRAS G13D-driven colorectal cancer in mouse xenograft models by upregulating GPX2 and targeting the mutant KRAS pocket. The work is mechanistically interesting and shows promising in vivo efficacy, but remains in the animal model phase with no human data, no comparative control arm efficacy reporting, and no published peer-review documentation in the source.
Preclinical in vivo xenograft studies (orthotopic, cell-derived, and patient-derived). KRAS G13D-mutant colorectal cancer in mouse models (orthotopic, CDX, and PDX). Intervention: Selenium nanoparticles (SeNPs) administered to upregulate GPX2 and target KRAS G13D mutant pocket.
In orthotopic CRC models, SeNPs significantly inhibited primary tumor growth and prevented liver metastasis In cell-derived xenograft (CDX) models, SeNPs achieved tumor inhibition rate of 70% In patient-derived xenograft (PDX) models, SeNPs achieved tumor inhibition rate of 61%
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding represents a potential first-in-class therapeutic avenue for KRAS G13D-driven CRC, which currently lacks specific inhibitors. However, clinical development and human efficacy trials are necessary before any clinical application can be considered.
First-in-class preclinical work demonstrating a novel nanoparticle approach in animal xenograft models; lacks human efficacy data, controlled comparators, and peer-reviewed publication details required for clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding represents a potential first-in-class therapeutic avenue for KRAS G13D-driven CRC, which currently lacks specific inhibitors. However, clinical development and human efficacy trials are necessary before any clinical application can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Despite substantial progress in KRAS‐targeted therapies, specific inhibitors of the KRAS G13D mutant remain unavailable. In a retrospective analysis, we found a notable downregulation of glutathione peroxidase 2 (GPX2) in KRAS G13D‐ mutant colorectal cancer (CRC), which correlated with poor outcomes. We hypothesized that GPX2 acts as a tumor suppressor and that its restoration could render KRAS G13D‐driven tumors vulnerable. In this study, we developed a selenium nanoparticle (SeNPs)‐based nanostrategy to suppress KRAS G13D‐driven tumors by modulating GPX2 expression. SeNPs upregulated GPX2 expression, thereby inhibiting metastasis through the GPX2‐HIF1α‐VEGF axis. Moreover, SeNPs release selenite (SeO 3 2− ) in situ, which interacts with the mutant pocket (residues 13–17) of the KRAS G13D protein. In vivo, this multimodal strategy demonstrated exceptional efficacy. In orthotopic CRC models, SeNPs significantly inhibited primary tumor growth and effectively prevented liver metastasis. In cell‑derived xenograft (CDX) and patient‐derived xenograft (PDX) models, SeNPs achieved tumor inhibition rates of 70% and 61%, respectively. Collectively, this study demonstrates the first‐in‐class therapeutic potential of SeNPs against this recalcitrant KRAS mutant and provides a novel nanoplatform for KRAS G13D‐targeted therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.